Nanoviricides - NNVC STOCK NEWS

NanoViricides has announced promising results for its broad-spectrum antiviral NV-387 in treating lethal RSV infections in animal models. When administered orally, NV-387 completely protected the animals, showing no lung damage and indicating a potential cure for RSV. Comparatively, animals treated with ribavirin showed severe lung damage and did not survive. NV-387 demonstrated efficacy with no adverse events in prior human trials and is set to progress to Phase II clinical trials. With no current approved safe treatment for RSV, NV-387 could address significant unmet medical needs, especially in vulnerable populations like infants and the elderly.

NanoViricides reported filing its Quarterly Report for the fiscal second quarter ending March 31, 2024. The report was submitted to the SEC on May 14, 2024. As of March 31, the company had $3.51 million in cash and equivalents, with an additional $2.5 million available, totaling $6 million. Property and equipment assets were reported at $7.92 million, with total liabilities standing at $0.81 million. The company utilized $4.84 million in net cash over nine months. Management voiced concerns about maintaining operations for the next 12 months without additional financing. NV-387, designed for broad-spectrum antiviral activity, is advancing to Phase II clinical trials for treating RSV under the US FDA. The Phase I trial for NV-CoV-2 (NV-387) in India concluded successfully, but the COVID treatment segment was incomplete due to a lack of patients. NanoViricides is seeking additional funding and exploring partnerships for NV-387, projecting significant market potential for their drug pipeline targeting various viral infections.

NanoViricides announced that its antiviral drug candidate, NV-387, showed complete survival in mice lethally infected with RSV (Respiratory Syncytial Virus) in a recent study.

The study compared NV-387 with the currently approved RSV treatment, ribavirin. While NV-387 led to the complete survival of animals over a 21-day period, ribavirin resulted in the death of all subjects by day 14.

RSV is a major cause of hospitalizations and deaths among children under 5 and adults over 65. The company's NV-387 is aimed to provide a safer and more effective treatment option for these vulnerable groups.

The company has completed Phase 1a/1b human clinical trials for NV-387 with no reported adverse events and plans to advance to Phase II trials for RSV treatment.

NanoViricides, Inc. (NYSE American:NNVC) announces participation in the EF Hutton Annual Global Conference on May 15, 2024, in New York City. The Company's President will discuss progress, particularly the promising antiviral drug NV-387. Successful completion of Phase 1a/1b clinical trials with no adverse events on healthy subjects indicates excellent safety. NV-387 demonstrates strong antiviral activity against various viruses and could potentially treat Coronaviruses, RSV, and Influenza A. Plans for Phase II trials and a pipeline of drug candidates are underway.

NanoViricides, Inc. announces NV-387, a novel broad-spectrum antiviral with activity against Smallpox/Mpox. NV-387 shows strong orthopoxvirus activity against Smallpox/Mpox, both inhalation and skin abrasion modes. Animal studies demonstrate increased survival compared to tecovirimat, approved for Smallpox. NV-387 potentially reduces tecovirimat resistance. NanoViricides focuses on developing antiviral nanomedicines for various viral infections.

NanoViricides, Inc. announces the development of NV-387, a broad-spectrum antiviral drug with strong activity against Influenza A viruses, potentially including Bird Flu H5N1 virus. In a study, NV-387 showed superior antiviral effects compared to three approved anti-influenza drugs. The company believes that NV-387 may have significant potential in treating various respiratory viruses.

NanoViricides, Inc. (NNVC) reports successful completion of Phase I NV-387 Clinical Trial in India. NV-387 has shown broad-spectrum antiviral activity against various viruses. Data lock is expected soon for further analysis. Plans for Phase II trials in progress, targeting RSV infections in adults, infants, and children. The potential market size for RSV therapeutics is estimated at $8.73 billion by 2031. NanoViricides' platform technology reduces the likelihood of viruses escaping treatment.

NanoViricides, Inc. reports strong financial status with $5.31 Million cash balance and $8.07 Million in assets as of December 31, 2023. The company's lead drug candidate NV-CoV-2 shows promise in treating various viral infections. Recent clinical trials demonstrate safety and tolerability of NV-387. The Company has taken steps to improve liquidity and expand drug pipeline addressing billion-dollar markets.

NanoViricides, Inc. (NNVC) has developed NV-CoV-2 oral drug products containing the active pharmaceutical ingredient NV-387, demonstrating strong safety and tolerability in clinical trials. The company believes that NV-387, an ultra-broad-spectrum antiviral nanomedicine, has long-term potential against many viruses, similar to antibiotics. The technology involves copying the host-side signature used by viruses to infect hosts, enabling a direct-acting antiviral that destroys the virus. NV-387 is designed to be active against a large number of viruses, with potential market sizes reaching billions of dollars. The strong safety and tolerability of NV-387 suggests it can be used across all patients, irrespective of age, co-morbidities, or disease severity, similar to antibiotics. NanoViricides aims to revolutionize antiviral treatment with NV-387.